Deepali Suri, President of ICON Biotech, has been published in Pharmaceutical Executive. Her article draws on insights from 163 biotech leaders across North America, EMEA and APAC, supported by a supplementary survey o...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
From biopsy bottlenecks to biomarker breakthroughs - how non-invasive tools are reshaping MASH trials
This article examines how non-invasive testing could transform the management of metabolic liver disease and help shape the future of MASH clinical development. It also outlines the rapidly evolving NIT landscape, emerging regulatory perspectives, and key opportunities to optimise MASH trial design and execution.
-
Advances in imaging biomarkers: Estimating efficacy with tumour growth rate modelling
Imaging biomarkers are an essential part of oncology trials, tracking the efficacy of the new treatment and comparing it to the existing gold standard therapies. The insights gleaned from imaging biomarkers steer the course of oncology clinical trials, informing decision-making and endpoints. This article discusses the benefits of tumour growth rate modelling.
-
Integration of AI in imaging clinical trials
In this article from Drug Discovery World, Sophie Winandy, Executive Director of Medical Imaging, explores the benefits of AI and how it can be integrated throughout medical imaging within clinical trials.
